Výsledky vyhledávání - "N. Dobrovolskaya"

Akademický článek

THE SPECIFIC FEATURES OF NEOPLASTIC PLEURISIES IN BREAST CANCER, BY USING THE DIAGNOSTIC CYTOLOGICAL TECHNIQUE

Autor: O. G. Grigoruk, L. M. Bazulina, L. N. Dobrovolskaya, T. A. Maximenko, M. N. Chechulin, A. F. Lazarev

Publikováno v: Опухоли женской репродуктивной системы, Vol 0, Iss 4, Pp 18-22 (2014)

The cytological characteristics of neoplastic pleurisies were studied in 119 patients with breast cancer. There were some cytological fea- tures of pleural fluid in breast cancer and particularities of the cell composition of pleurisies with ductal a

Externí odkaz: https://doaj.org/article/f0f58662607f432fb2216ddc63f3e95d

Zobrazit plný text záznamu

Akademický článek

Peculiarities of carcinomatous pleurisies in breast cancer (cytological diagnostic method)

Autor: O. G. Grigoruk, L. M. Bazulina, L. N. Dobrovolskaya, T. A. Maksimenko, M. N. Chechulin, A. F. Lazarev

Publikováno v: Опухоли женской репродуктивной системы, Vol 0, Iss 1, Pp 10-14 (2014)

The specific features of carcinomatous pleurisies were studied in 119 patients with breast cancer (BC). The most characteristic properties of the structure of cells and the composition of pleural fluid were noted in infiltrating ductal and lobular BC

Externí odkaz: https://doaj.org/article/c6d0d220ed1e4b88bfce4ae17ac73815

Zobrazit plný text záznamu

P5-19-01: Final Results of a Three-Arm Randomised Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines

Autor: Fawzia Mefti, N. Dobrovolskaya, S. Tjulandin, Mario Campone, S.C. Chen, F. Lefresne, S.J. Fourié, N Meheust, Jacek Jassem, M. Konstantinova

Publikováno v: Cancer Research. 71:P5-19

Purpose: Owing to the increasing number of patients treated with anthracycline-based adjuvant chemotherapy, there is a need for new effective and tolerable non-anthracycline based regimens in metastatic breast cancer. Patients and methods: Patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75ad549b62bd56bbe5368822f84c4170
https://doi.org/10.1158/0008-5472.sabcs11-p5-19-01

Zobrazit plný text záznamu

EP-1060: Dose reduction of postmastectomy radiation in the management of local breast cancer

Autor: E. Khmelevsky, N. Dobrovolskaya, Y. Ponkratova

Publikováno v: Radiotherapy and Oncology. 106

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::809698e3fc2ef0011d65ba66c342c29d

Zobrazit plný text záznamu

1857 Final results of a phase II study evaluating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial)

Autor: G. Villanova, Nicole Tubiana-Mathieu, Enrique Espinosa, Guenther G. Steger, P. Landreau, M. Blasinska, A. Ardizzoia, Francesco Giotta, A. Dominguez, N. Dobrovolskaya

Publikováno v: European Journal of Cancer. 51:S284

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5524b6154d7ad903b4ebf757af79ba6f
https://doi.org/10.1016/s0959-8049(16)30807-3

Zobrazit plný text záznamu

Phase Ii Study Evaluating Oral Vinorelbine As a Single-Agent As First-Line Chemotherapy for Metastatic Breast Cancer Patients with Bone Metastases (Norbreast-228 Trial): First Efficacy Results

Publikováno v: Annals of Oncology. 25:iv132

Background: Oral chemotherapy (CT) is a widely recognized treatment option for hormone receptor positive, metastatic breast cancer (MBC) patients (pts) pretreated by hormone therapy (HT). In this phase II study, we evaluated the efficacy and safety o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a69e621cc32f6fcc146133b2400ff7c7
https://doi.org/10.1093/annonc/mdu329.52

Zobrazit plný text záznamu

5000 A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines

Autor: S.J. Fourié, S. Tjulandin, J.C. Pouget, F. Lefresne, N. Dobrovolskaya, F. Mefti, Mario Campone, Jacek Jassem, M. Konstantinova, S.C. Chen

Publikováno v: European Journal of Cancer Supplements. 7:259

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20e3a2f2170514d80bb06e318ca454ee
https://doi.org/10.1016/s1359-6349(09)70892-4

Zobrazit plný text záznamu

Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+ metastatic breast cancer (MBC)

Autor: N Dobrovolskaya, Tadeusz Pienkowski, C Oliva, A Knott, A Jagiello-Gruszfeld, M DeSilvio, Alexey Manikhas, S Tjulandin Sergei

Publikováno v: Cancer Research. 69:3145

CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #3145 L, an oral tyrosine kinase inhibitor of EGFR/HER2, is active as monotherapy and in combination with chemotherapy for HER2+ MBC. In a planned subgroup analysis of a Ph III tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ebaeaf63cc8b141c907bd5f849d358f
https://doi.org/10.1158/0008-5472.sabcs-3145

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání